• George Liamis, Theodosios D Filippatos, and Moses S Elisaf.
• Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
• Expert Rev Clin Pharmacol. 2014 Jul 1; 7 (4): 431-41.

AbstractHyponatremia is the most common electrolyte disorder and is associated with serious neurologic sequelae and increased mortality. Conventional treatment options for hyponatremia, such as fluid restriction, hypertonic saline, loop diuretics, demeclocycline or urea, are ineffective in the long-term. The present review considers the role of vasopressin receptor inhibitors (vaptans), focusing on lixivaptan, in the treatment of patients with euvolemic or hypervolemic hyponatremia. Lixivaptan is an oral selective V2 receptor inhibitor, which produces a significantly greater increase of serum sodium levels compared with placebo. These effects seem promising, but more trials are needed to examine whether the beneficial effect of lixivaptan on serum sodium concentration translates into clinical benefit in these patient populations.

20 keywords...

hide…